Marquet Magda 4

4 · Immix Biopharma, Inc. · Filed May 29, 2026

AI-generated summary of this filing

Updated May 29, 2026

Immix Biopharma Director Magda Marquet Receives 18,750-Share Award

What Happened

Director Magda Marquet received equity awards from Immix Biopharma (IMMX) on May 22, 2026. The filing shows two grants totaling 18,750 shares: 6,250 restricted stock units (RSUs) and a 12,500-share derivative award (stock option/other derivative). Both awards were granted at a $0 acquisition price (i.e., they were awards, not purchases).

Key Details

Transaction date: May 22, 2026; Filing date: May 29, 2026 (filed 7 days after the grants).
Awards: 6,250 RSUs + 12,500-share derivative award = 18,750 total shares; acquisition price $0 for each grant.
Vesting:
- 6,250 RSUs vest in full on the earlier of the one-year anniversary of the grant or the Issuer’s 2027 annual meeting, subject to continued service (Footnote F1).
- The 12,500 derivative award vests in substantially equal monthly installments over 12 months (or any remaining unvested portion vests on the 2027 annual meeting if it occurs earlier), subject to continued board service (Footnote F3).
Shares owned after the transaction are not specified in the excerpt provided. Footnote F2 notes Marquet’s association with Alma Life Sciences, LLC and that she may be deemed to beneficially own securities held by that entity, though she disclaims beneficial ownership except to the extent of pecuniary interest.
Timeliness: The Form 4 was filed 7 days after the transaction date, later than the typical two-business-day reporting window for Form 4s.

Context

These were awarded grants (compensation/retention), not open-market purchases or sales; awards are common for directors and are subject to vesting and continued service conditions.
The 12,500-share item is a derivative award (an option-like instrument) that vests over time—it is not an immediate sale or cash transaction.
The late filing may delay market visibility into insider compensation but does not, by itself, indicate intent or opinion about the company’s prospects.

Form 4

Period: 2026-05-22

Director

Transactions

Award
Common Stock
[F1]
2026-05-22+6,250→ 52,342 total
Award
Stock Option (Right to Buy)
[F3]
2026-05-22+12,500→ 12,500 total
Exercise: $8.78Exp: 2036-05-22→ Common Stock (12,500 underlying)

Holdings

Footnotes (3)

[F1]The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.
[F2]The Reporting Person is the Co-Founder and Co-Chief Executive Officer of Alma Life Sciences, LLC and may be deemed to beneficially own the securities held by Alma Life Sciences, LLC. The Reporting Person disclaims beneficial ownership of the common stock owned directly by Alma Life Sciences, LLC, except to the extent of her pecuniary interest therein.
[F3]The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.

Signature

/s/ Ilya Rachman as Attorney-In-Fact for Magda Marquet|2026-05-29

1 file